ICI Combinations Show Survival Benefits in Heavily Pretreated MSS mCRC
• A study in China found that immune checkpoint inhibitor (ICI)-based treatments improved survival in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients.
• Combinations of ICI with tyrosine kinase inhibitors (TKIs), with or without chemotherapy, demonstrated meaningful survival improvements and a manageable safety profile.
• Another phase 2 trial showed that GRANITE, combined with ICIs and bevacizumab/chemotherapy, improved progression-free survival (PFS) in first-line MSS mCRC, especially in patients with low ctDNA levels.
• These findings support further investigation of immunotherapy rechallenge and personalized neoantigen targeting in MSS mCRC, addressing a critical unmet need.
© Copyright 2025. All Rights Reserved by MedPath